Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: (914) 847-7000Website: https://www.regeneron.com/Careers: careers.regeneron.com
Latest news
- FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab-gcpt) for Treatment of Relapsed or Refractory Multiple Myeloma
2 July 2025 - Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
20 June 2025 - Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
22 May 2025 - Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
18 April 2025 - Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
26 February 2025 - Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
11 February 2025 - FDA Revokes EUA for REGEN-COV (casirivimab and imdevimab) for the Treatment of COVID-19
13 December 2024 - Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
9 December 2024 - Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
27 September 2024 - Dupixent Approved in the US as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
13 September 2024
Drugs Associated with Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 10 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Arcalyst
Generic name: rilonacept Drug class: interleukin inhibitors |
5 reviews | 10 / 10 |
|
Dupixent
Generic name: dupilumab Drug class: interleukin inhibitors |
498 reviews | 7.3 / 10 |
|
Evkeeza
Generic name: evinacumab Drug class: miscellaneous antihyperlipidemic agents |
||
|
Eylea
Generic name: aflibercept Drug class: anti-angiogenic ophthalmic agents |
70 reviews | 7.1 / 10 |
|
Eylea HD
Generic name: aflibercept Drug class: anti-angiogenic ophthalmic agents |
4 reviews | 7.5 / 10 |
|
Kevzara
Generic name: sarilumab Drug class: antirheumatics, interleukin inhibitors |
30 reviews | 6.9 / 10 |
|
Libtayo
Generic name: cemiplimab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
9 reviews | 8.4 / 10 |
|
Lynozyfic
Generic name: linvoseltamab |
||
|
Praluent
Generic name: alirocumab Drug class: PCSK9 inhibitors |
304 reviews | 6.3 / 10 |
|
Veopoz
Generic name: pozelimab Drug class: selective immunosuppressants |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||